# ![@stellanewslife Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1292752935533686785.png) @stellanewslife STELLANEWS.LIFE

STELLANEWS.LIFE posts on X about core, strong, novo, japan the most. They currently have [-----] followers and [--] posts still getting attention that total [-----] engagements in the last [--] hours.

### Engagements: [-----] [#](/creator/twitter::1292752935533686785/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1292752935533686785/c:line/m:interactions.svg)

- [--] Week [-----] +7,896%
- [--] Month [-----] +47%
- [--] Months [------] +98%
- [--] Year [------] +835%

### Mentions: [--] [#](/creator/twitter::1292752935533686785/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1292752935533686785/c:line/m:posts_active.svg)

- [--] Week [--] -44%
- [--] Month [--] -7.20%
- [--] Months [---] +63%
- [--] Year [---] +542%

### Followers: [-----] [#](/creator/twitter::1292752935533686785/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1292752935533686785/c:line/m:followers.svg)

- [--] Week [-----] +0.60%
- [--] Month [-----] +1.10%
- [--] Months [-----] +26%
- [--] Year [-----] +39%

### CreatorRank: [-------] [#](/creator/twitter::1292752935533686785/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1292752935533686785/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  20% [currencies](/list/currencies)  7.27% [countries](/list/countries)  7.27% [travel destinations](/list/travel-destinations)  3.64% [cryptocurrencies](/list/cryptocurrencies)  1.82% [exchanges](/list/exchanges)  1.82%

**Social topic influence**
[core](/topic/core) 12.73%, [strong](/topic/strong) 7.27%, [novo](/topic/novo) #2414, [japan](/topic/japan) 5.45%, [regeneron](/topic/regeneron) #2, [company](/topic/company) #380, [shanghai](/topic/shanghai) #548, [the first](/topic/the-first) 1.82%, [$4503t](/topic/$4503t) 1.82%, [$4536t](/topic/$4536t) 1.82%

**Top accounts mentioned or mentioned by**
[@prevononet](/creator/undefined) [@hifukonews](/creator/undefined)

**Top assets mentioned**
[The 99% Community (99)](/topic/$99) [Gilead Sciences, Inc. (GILD)](/topic/gilead-sciences) [Eli Lilly and Company (LLY)](/topic/eli-lilly) [Sanofi (SNY)](/topic/sanofi) [Novartis AG (NVS)](/topic/novartis) [Johnson & Johnson (JNJ)](/topic/johnson-johnson) [AbbVie Inc (ABBV)](/topic/$abbv)
### Top Social Posts
Top posts by engagements in the last [--] hours

"Astellas Reports Financial Results for the First Nine Months of FY2025 Revenue: [------] billion (+10.2% YoY) 🔹 Core operating profit: [-----] billion (+48.6% YoY) 🔹 Core profit: [-----] billion (+48.7% YoY) 🔹 Core EPS: 185.20Astellas reported strong year-on-year growth for the first nine months of FY2025 driven by Strategic Brands including PADCEV IZERVAY VYLOY and VEOZAH as well as continued expansion of XTANDI.Cost optimization initiatives under SMT also contributed to the significant profit increase"  
[X Link](https://x.com/stellanewslife/status/2021582226488692850)  2026-02-11T13:48Z [----] followers, [--] engagements


"📷 📷 📷    # # #"  
[X Link](https://x.com/stellanewslife/status/2021596644836528422)  2026-02-11T14:46Z [----] followers, [---] engagements


"loncastuximab tesirine1/2 r/r DLBCL ✔ CD19loncastuximab tesirine1/2 ✔ Br/r DLBCL ✔ [--] CD19loncastuximab tesirineB1/2MT-2111-A-101 [---] DLBCL2 #DLBCL # #"  
[X Link](https://x.com/stellanewslife/status/2021544485457682566)  2026-02-11T11:18Z [----] followers, [--] engagements


"202633 ✔ 347718.61094408.5 ✔ ✔ [----------------------] [--] [-------] # # #"  
[X Link](https://x.com/stellanewslife/status/2021536996666011753)  2026-02-11T10:49Z [----] followers, [---] engagements


"Regeneron2025143Dupixent 🔹 2025143+1% 🔹 438.8+3% 🔹 Dupixent178+26% Regeneron20254DupixentEYLEA HDEYLEA [----] #Regeneron # # #Dupixent #EYLEA"  
[X Link](https://x.com/stellanewslife/status/2021579449884660097)  2026-02-11T13:37Z [----] followers, [----] engagements


"Novo Nordisk 🔹 [-------] 🔹 Novo Nordisk A/S Novo Nordisk2018Thomas Rantzau22 Tanja Villumsen #NovoNordisk # # #"  
[X Link](https://x.com/stellanewslife/status/2021584315218600385)  2026-02-11T13:57Z [----] followers, [--] engagements


"Novo Nordisk2025DKK 3090CER10 🔹 DKK [-----] billion6CER10 🔹 DKK [-----] billion1CER6 🔹 DKK [-----] billion1 🔹 EPSDKK [------] DKK [-----] billion7CER10 26CER31 GLP-1Wegovy pillsemaglutide 25mg20261512350000 2026CER513 2025DKK 7.95DKK [-----] DKK [---] #NovoNordisk # #GLP1 # #"  
[X Link](https://x.com/stellanewslife/status/2021584771122712775)  2026-02-11T13:59Z [----] followers, [--] engagements


"202633 ✔ 21085.434820.3 ✔ ✔ [-------------------] [--] # # #"  
[X Link](https://x.com/stellanewslife/status/2021536556994232827)  2026-02-11T10:47Z [----] followers, [--] engagements


"20263 3IFRS Santen Pharmaceutical Co. Ltd. Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March [--] [----] (IFRS) For the nine months ended December [--] [----] revenue decreased [---] year on year to JPY [-----] billion while core operating profit declined [----] to JPY [----] billion. Operating profit under full IFRS fell [----] to JPY [----] billion. In Japan results were affected by NHI price revisions and the impact of policy changes related to long-listed products. China remained broadly flat excluding foreign exchange effects despite inventory adjustments. Asia (excluding"  
[X Link](https://x.com/stellanewslife/status/2021536593702723779)  2026-02-11T10:47Z [----] followers, [--] engagements


"loncastuximab tesirine1/2DLBCL Tanabe Pharma: Phase 1/2 Study of Loncastuximab Tesirine in Japan Meets Primary Endpoint in r/r DLBCL Tanabe Pharma announced that a domestic Phase 1/2 bridging study of loncastuximab tesirine met its primary endpoint in patients with relapsed or refractory diffuse large B-cell lymphoma r/r DLBCL. The open-label single-arm multicenter study MT-2111-A-101 enrolled [--] patients in Japan. The primary endpoint was overall response rate assessed by independent central review. According to the company the study achieved this endpoint. The safety profile was reported to"  
[X Link](https://x.com/stellanewslife/status/2021544584812048688)  2026-02-11T11:19Z [----] followers, [--] engagements


"Astellas2025310.2%48.6% 🔹 1601310.2% 🔹 442148.6% 🔹 331648.7% 🔹 EPS185.2048.6% [--------] PADCEVIZERVAYVYLOYVEOZAHXTANDI SMT # # # #StrategicBrands"  
[X Link](https://x.com/stellanewslife/status/2021582065448473008)  2026-02-11T13:48Z [----] followers, [--] engagements


"New employee representative on the Board of Directors of Novo Nordisk A/S Date: January [--] [----] 🔹 Company announcement No. [--] / 2026Novo Nordisk announced that Thomas Rantzau employee representative on the Board since [----] has decided to step down after [--] years with the company.His alternate Tanja Villumsen has joined the Board of Directors as employee representative with immediate effect.#NovoNordisk #CorporateGovernance #BoardOfDirectors #HealthcareIndustry"  
[X Link](https://x.com/stellanewslife/status/2021584385955242415)  2026-02-11T13:57Z [----] followers, [--] engagements


"Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK [-----] billion in [----] 📅 February [--] [----] (Company announcement No. [--] / 2026) Novo Nordisk reported [----] net sales of DKK [-----] billion (+6% reported +10% CER). Operating profit reached DKK [-----] billion (1% reported +6% CER) while net profit was DKK [-----] billion and diluted EPS DKK [-----]. Obesity care grew 26% (31% CER) and GLP-1 diabetes sales increased 2% (6% CER). The company launched oral Wegovy in the U.S. in January [----] with weekly prescriptions reaching [-----] shortly after launch. For"  
[X Link](https://x.com/stellanewslife/status/2021584890723180707)  2026-02-11T13:59Z [----] followers, [--] engagements


"Amgen2025368EPS 🔹 2025368+10% 🔹 499+9% 🔹 GAAP EPS14.23+88% 🔹 Non-GAAP EPS21.84+10% Amgen20252351+10%181410 Repatha+36%EVENITY+34%TEZSPIRE+52%UPLIZNA+73%Enbrel33%XGEVA6% GAAP91+25%25.8% [--] [----] 📌 [------] 📌 GAAP EPS15.4516.94 📌 Non-GAAP EPS21.6023.00 #Amgen # # # #"  
[X Link](https://x.com/stellanewslife/status/2021588938805113163)  2026-02-11T14:15Z [----] followers, [--] engagements


"Gilead2025294 Biktarvy143 Gilead Sciences20254 📷 2025294+2% 📷 289+1% 📷 Veklury280+4% 📷 EPS6.780.38 📷 Non-GAAP EPS8.154.62 HIVBiktarvy143+7% Descovy28+31% COVID-19Veklury9.11-49% 📷 [----] [------] EPS6.757.15 Non-GAAP EPS8.458.85 HIV2026 #Gilead # #HIV # #"  
[X Link](https://x.com/stellanewslife/status/2021596208419189011)  2026-02-11T14:44Z [----] followers, [--] engagements


"✔ ✔ ✔    # # #"  
[X Link](https://x.com/stellanewslife/status/2021604809443541321)  2026-02-11T15:18Z [----] followers, [--] engagements


"AstraZeneca results: FY and Q4 [----]  AstraZeneca reported FY2025 total revenue of $58739 million up 8% at constant exchange rates with growth across Oncology CVRM Respiratory & Immunology and Rare Disease. Core EPS increased 11% to $9.16. The company announced [--] positive Phase [--] readouts and [--] approvals in major regions over the past twelve months. More than [---] Phase [--] trials are ongoing with over [--] additional Phase [--] readouts expected in [----]. Guidance for FY2026 indicates: Total Revenue expected to increase by a mid-to-high single-digit percentage at CER. Core EPS expected to increase"  
[X Link](https://x.com/stellanewslife/status/2021604856310763699)  2026-02-11T15:18Z [----] followers, [--] engagements


"AstraZeneca results: FY and Q4 [----]  AstraZeneca reported FY2025 total revenue of $58739 million up 8% at constant exchange rates with growth across Oncology CVRM Respiratory & Immunology and Rare Disease. Core EPS increased 11% to $9.16. The company announced [--] positive Phase [--] readouts and [--] approvals in major regions over the past twelve months. More than [---] Phase [--] trials are ongoing with over [--] additional Phase [--] readouts expected in [----]. Guidance for FY2026 indicates: Total Revenue expected to increase by a mid-to-high single-digit percentage at CER. Core EPS expected to increase"  
[X Link](https://x.com/stellanewslife/status/2021604975286407204)  2026-02-11T15:19Z [----] followers, [--] engagements


"2025436 ✔ [--------------] ✔ [------] ✔ [-----] 20254202543626009.91EPS7.8315.0 413.34232.2202.5 236.62025103COAST 2SHORE3 20261EPS # # #"  
[X Link](https://x.com/stellanewslife/status/2021607948758507549)  2026-02-11T15:31Z [----] followers, [--] engagements


"Merck & Co. Inc. Rahway N.J. USA Announces Fourth-Quarter and Full-Year [----] Financial Results; Highlights Progress Advancing Broad Diverse Pipeline [-----] Merck reported full-year [----] worldwide sales of $65.0 billion up 1% (2% ex-FX). Fourth-quarter sales were $16.4 billion increasing 5%. KEYTRUDA/KEYTRUDA QLEX (pembrolizumab) generated $31.7 billion in [----] up 7%. WINREVAIR (sotatercept) sales reached $1.4 billion and CAPVAXIVE recorded $759 million. GARDASIL/GARDASIL [--] sales declined 39% to $5.2 billion primarily reflecting lower demand in China. Full-year GAAP EPS was $7.28 and non-GAAP"  
[X Link](https://x.com/stellanewslife/status/2021613980935238087)  2026-02-11T15:55Z [----] followers, [--] engagements


"2025545 [--] ✔ [--------] ✔ 40.1EPS8.98 ✔ [------] 20255453200821889001440.1EPS8.9817 [-----] 20253FDA [------] # # #"  
[X Link](https://x.com/stellanewslife/status/2021614574974468541)  2026-02-11T15:57Z [----] followers, [--] engagements


"20263 3IFRS Sumitomo Pharma Co. Ltd. Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March [--] [----] (IFRS) For the nine months ended December [--] [----] revenue increased [----] year on year to JPY [-----] billion. Core operating profit rose [-----] to JPY [-----] billion while operating profit reached JPY [-----] billion. Growth was primarily driven by North America where relugolix ORGOVYX for advanced prostate cancer and vibegron GEMTESA for overactive bladder expanded sales. A sales milestone related to ORGOVYX was also recorded. In Japan revenue declined due to the loss"  
[X Link](https://x.com/stellanewslife/status/2021537035354607665)  2026-02-11T10:49Z [----] followers, [---] engagements


"Regeneron Reports Fourth Quarter and Full Year [----] Financial and Operating Results Regeneron reported full-year [----] revenue of $14.3 billion (+1% YoY) and fourth-quarter revenue of $3.9 billion (+3% YoY). Global net sales of Dupixent reached $17.8 billion for the year (+26%) while EYLEA HD continued to grow in the U.S. The company also provided [----] financial guidance and outlined multiple regulatory milestones across ophthalmology immunology oncology and rare diseases"  
[X Link](https://x.com/stellanewslife/status/2021579534659998136)  2026-02-11T13:38Z [----] followers, [---] engagements


"AMGEN REPORTS FOURTH QUARTER AND FULL YEAR [----] FINANCIAL RESULTS 📅 February [--] [----] Amgen reported strong [----] financial performance with full-year revenue increasing 10% year-over-year to $36.8 billion and GAAP EPS rising 88% to $14.23. Fourth-quarter revenue reached $9.9 billion (+9%) supported by 7% product sales growth driven by 10% volume growth. Key growth drivers included: Repatha: $3.0B FY sales (+36%) EVENITY: $2.1B (+34%) TEZSPIRE: $1.48B (+52%) UPLIZNA: $655M (+73%) For [----] Amgen expects revenue of $37.0$38.4 billion and non-GAAP EPS of $21.60$23.00. The company also generated"  
[X Link](https://x.com/stellanewslife/status/2021589026290184393)  2026-02-11T14:15Z [----] followers, [--] engagements


"Gilead Sciences Announces Fourth Quarter and Full Year [----] Financial Results FOSTER CITY Calif. February [--] [----] Gilead Sciences (Nasdaq: GILD) reported full year [----] revenues of $29.4 billion up 2% year over year. Product sales excluding Veklury rose 4% to $28.0 billion. Full year HIV sales increased 6% to $20.8 billion led by: Biktarvy: $14.3 billion (+7%) Descovy: $2.8 billion (+31%) Fourth quarter [----] revenues were $7.9 billion (+5%) with diluted EPS of $1.74 (non-GAAP $1.86). For [----] Gilead expects product sales of $29.630.0 billion and non-GAAP EPS of $8.458.85. #Gilead #Earnings"  
[X Link](https://x.com/stellanewslife/status/2021596259161965019)  2026-02-11T14:44Z [----] followers, [--] engagements


"Lilly reports fourth-quarter [----] financial results and provides [----] guidance Eli Lilly and Company reported a 43% year-over-year increase in Q4 [----] revenue to $19.3 billion primarily driven by volume growth of tirzepatide marketed as Mounjaro for type [--] diabetes and Zepbound for obesity. Key highlights: Q4 [----] EPS increased to $7.39 (reported) and $7.54 (non-GAAP) both including $0.52 of acquired IPR&D charges. Mounjaro revenue reached $7.4 billion (+110%) while Zepbound generated $4.2 billion in the U.S. (+122%). [----] guidance projects revenue of $80$83 billion and non-GAAP EPS of"  
[X Link](https://x.com/stellanewslife/status/2021596695092719821)  2026-02-11T14:46Z [----] followers, [--] engagements


"Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in [----] [--------] Sanofi reported FY2025 net sales of [-----] million up 9.9% at constant exchange rates. Business EPS reached [----] increasing 15.0% at CER while IFRS EPS was [----] for the full year. In Q4 [----] sales grew 13.3% at CER. Dupixent (dupilumab) sales increased 32.2% to [---] billion while vaccines sales declined 2.5% to [---] billion. Business EPS for the quarter was [----] up 26.7% at CER; IFRS EPS was [-----]. Pipeline updates included: Ten regulatory approvals across immunology and rare diseases."  
[X Link](https://x.com/stellanewslife/status/2021608101510860897)  2026-02-11T15:31Z [----] followers, [--] engagements


"2025650 [---] ✔ [--------] ✔ QLEX3177 ✔ 2026Non-GAAP EPS5.005.15 [-------------------] QLEX317714217.5993952 GAAP EPS7.28Non-GAAP EPS8.982026655670Non-GAAP EPS5.005.1536.513.65 [--------------] # # #"  
[X Link](https://x.com/stellanewslife/status/2021613888668827987)  2026-02-11T15:54Z [----] followers, [--] engagements


"Novartis delivered high single-digit sales growth achieved 40% core margin and further advanced the pipeline in [----] [----] Novartis reported FY2025 net sales of $54.5 billion up 8% at constant currencies. Core operating income increased 14% (cc) reaching a core margin of 40.1%. Core EPS rose 17% (cc) to $8.98. Growth was driven by priority brands including Kisqali (+57% cc) Kesimpta (+36% cc) Pluvicto (+42% cc) Scemblix (+85% cc) and Cosentyx (+8% cc). In Q4 net sales were $13.3 billion (1% cc) impacted by U.S. generic erosion and revenue deduction adjustments. Core operating income increased"  
[X Link](https://x.com/stellanewslife/status/2021614670592024750)  2026-02-11T15:57Z [----] followers, [--] engagements


"2025942 [--------] ✔ [----------] ✔ EPS11.03EPS10.79 ✔ [--------] 2025494193006.05.3 424564009.14EPS2.10EPS2.4610.10 Innovative Medicine6045.3MedTech3385.4 202610001010EPS11.4311.63 # # #"  
[X Link](https://x.com/anyuser/status/2021615164685205876)  2026-02-11T15:59Z [----] followers, [--] engagements


"Johnson & Johnson reports Q4 and Full-Year [----] results [-----] Johnson & Johnson reported full-year [----] sales of $94.2 billion up 6.0% year over year with operational growth of 5.3%. Diluted EPS was $11.03 and adjusted EPS was $10.79. Fourth-quarter sales were $24.6 billion increasing 9.1%. Q4 EPS was $2.10 and adjusted EPS was $2.46 both including a $(0.10) impact related to the acquisition of Halda Therapeutics. Innovative Medicine delivered $60.4 billion in full-year sales (+5.3% operational) driven by DARZALEX CARVYKTI ERLEADA and RYBREVANT/LAZCLUZE partially offset by STELARA erosion."  
[X Link](https://x.com/stellanewslife/status/2021615254313255002)  2026-02-11T16:00Z [----] followers, [--] engagements


"2025611.6 2026EPS14.3714.57 ✔ [--------------] ✔ EPS10.00IPR&D12.76 ✔ 2026EPS14.3714.57 2025461160008.68.5GAAPEPS2.36EPS10.00IPR&D12.76 30414.017562008340045400049.5 107670019.63769003621006655001.54860006.1 4166180010.0EPS2.71 2026EPS14.3714.57IPR&D #AbbVie #"  
[X Link](https://x.com/anyuser/status/2021615719822278688)  2026-02-11T16:02Z [----] followers, [--] engagements


"AbbVie Reports Full-Year and Fourth-Quarter [----] Financial Results reported full-year [----] net revenues of $61.160 billion up 8.6% reported (8.5% operational). GAAP diluted EPS was $2.36 and adjusted diluted EPS was $10.00 including an unfavorable $2.76 per share impact from acquired IPR&D and milestones expense.Immunology delivered $30.406 billion (+14.0%) driven by Skyrizi ($17.562 billion) and Rinvoq ($8.304 billion) partially offset by Humira ($4.540 billion -49.5%). Neuroscience grew 19.6% to $10.767 billion while Oncology increased 1.5% to $6.655 billion. Aesthetics declined 6.1% to"  
[X Link](https://x.com/stellanewslife/status/2021615802781409551)  2026-02-11T16:02Z [----] followers, [--] engagements


"20257 🔹 2025615CER7 🔹 [--] 🔹 EPS11IFRS58 🔹 2026EPS 20256151600CER7CHF248 47669009A [--------] 218330013EPS19.4611IFRS137990058 [-------] 2026EPS #Roche # #"  
[X Link](https://x.com/stellanewslife/status/2021617993005052149)  2026-02-11T16:11Z [----] followers, [--] engagements


"Roche reports strong [----] results with 7% sales growth [----] Roche reported [----] group sales of CHF [-----] million up 7% at constant exchange rates (2% in CHF). Core operating profit increased 13% and core EPS rose 11% to CHF [-----]. IFRS net income climbed 58% to CHF [-----] million. Pharmaceuticals sales grew 9% to CHF [-----] million driven by Phesgo Xolair Ocrevus Hemlibra and Vabysmo. Diagnostics sales increased 2% to CHF [-----] million supported by pathology and molecular testing demand. For [----] Roche expects mid single-digit sales growth and high single-digit core EPS growth (CER). The Board"  
[X Link](https://x.com/stellanewslife/status/2021618106360283216)  2026-02-11T16:11Z [----] followers, [--] engagements


"FDALEQEMBI IQLIK1 PDUFA524 🔹 FDA1500mgsBLA 🔹 PDUFA2026524 🔹 IV BiogenALEQEMBI IQLIK1sBLAFDA IV1500mg 3Clarity ADOLE1IV IV2 360mg20258 #FDA #LEQEMBI # #"  
[X Link](https://x.com/stellanewslife/status/2021621501078983096)  2026-02-11T16:25Z [----] followers, [--] engagements


"FDA Accepts sBLA for Weekly Subcutaneous LEQEMBI IQLIK as Initial Therapy  FDA has accepted a supplemental BLA for weekly (500mg) subcutaneous dosing of lecanemab (LEQEMBI IQLIK) as initial therapy for early Alzheimers disease and granted Priority Review. The PDUFA action date is May [--] [----]. The filing is supported by a sub-study from the Phase [--] Clarity AD open-label extension reporting comparable exposure and similar clinical and biomarker effects versus biweekly IV dosing. Safety was described as consistent with IV administration with systemic injection-related reactions occurring in less"  
[X Link](https://x.com/stellanewslife/status/2021621797771477308)  2026-02-11T16:26Z [----] followers, [--] engagements


"HenliusPD-1serplulimab 🔹 🔹 [--] 🔹 [----] 🔹 [----] Shanghai Henlius BiotechPD-1serplulimab ES-SCLC22026 [-------------] # #Henlius #PD1 #"  
[X Link](https://x.com/stellanewslife/status/2021622385057898764)  2026-02-11T16:28Z [----] followers, [--] engagements


"Eisai Partners with Shanghai Henlius on Anti-PD-1 Antibody Serplulimab in Japan and Shanghai Henlius announced a license agreement granting Eisai exclusive commercialization rights to the anti-PD-1 antibody serplulimab in Japan along with joint development and manufacturing as Japan a Phase [--] bridging study in extensive-stage small cell lung cancer is ongoing and a regulatory filing is planned within fiscal year 2026.The deal includes an upfront payment of $75 million regulatory milestones of up to $80.01 million sales milestones of up to $233.30 million and double-digit percentage royalties"  
[X Link](https://x.com/stellanewslife/status/2021622557754150913)  2026-02-11T16:29Z [----] followers, [--] engagements


"NMPA 🔹 BLA 🔹 1500mg 🔹 🔹 [-----] BiogenBLANMPA 20261211500mg 250mg2115NMPA # # #NMPA #"  
[X Link](https://x.com/stellanewslife/status/2021622991256465445)  2026-02-11T16:30Z [----] followers, [--] engagements


"YCANTH0.71 🔹 [------] 🔹 [-----] 🔹 [--] YCANTH0.71 20259192025111214995.600.45mL [-----] [--] # # #YCANTH #"  
[X Link](https://x.com/stellanewslife/status/2021623364419465616)  2026-02-11T16:32Z [----] followers, [--] engagements


"Shionogi Group Launches YCANTH 0.71% Topical Solution in Japan for Molluscum Contagiosum announced that its group company Torii Pharmaceutical has launched YCANTH topical solution 0.71% (cantharidin) in Japan for the treatment of molluscum contagiosum.The product was approved in September [----] and listed under the NHI price system in November [----]. It is indicated for patients aged [--] years and older applied every three weeks and washed off after [----] hours.According to the company a Japan Phase [--] clinical program met the primary endpoint versus vehicle with safety and tolerability"  
[X Link](https://x.com/stellanewslife/status/2021623464176841176)  2026-02-11T16:32Z [----] followers, [--] engagements


"SCS575DRG73 🔹 SCS575 🔹 DRG573834 🔹 MRIFDA NANS 2026SCS575 Proclaim DRG834573 Proclaim SCSEterna SCSProclaim DRGMRIFDA # #SCS #DRG # #"  
[X Link](https://x.com/anyuser/status/2021623835834118567)  2026-02-11T16:34Z [----] followers, [--] engagements


"Abbott Reports 75% Reduction in Pain-Related Healthcare Visits at [--] Years with SCS SCS575 Abbott presented five-year real-world data at NANS [----] showing an average 75% reduction in pain-related healthcare visits among patients treated with its spinal cord stimulation (SCS) systems. For its Proclaim DRG system a retrospective study of [---] patients reported a 73% average reduction in pain-related healthcare utilization at five years. The company also announced FDA approval allowing prone-position MRI access for certain neuromodulation systems potentially expanding imaging options requiring"  
[X Link](https://x.com/stellanewslife/status/2021623929979429199)  2026-02-11T16:34Z [----] followers, [--] engagements


"RT @prevononet: [--------------] # #"  
[X Link](https://x.com/anyuser/status/2021741160839118959)  2026-02-12T00:20Z [----] followers, [--] engagements


"RT @prevononet: NHS HPV254935 PREVONO # #"  
[X Link](https://x.com/anyuser/status/2021741221690191988)  2026-02-12T00:20Z [----] followers, [--] engagements


"RT @prevononet:  Vol.1 PREVONO # #"  
[X Link](https://x.com/anyuser/status/2021741273686978922)  2026-02-12T00:20Z [----] followers, [--] engagements


"RT @prevononet:  PREVONO"  
[X Link](https://x.com/anyuser/status/2021741353403838760)  2026-02-12T00:21Z [----] followers, [--] engagements


"RT @hifuko_news:"  
[X Link](https://x.com/anyuser/status/2021839742346969500)  2026-02-12T06:52Z [----] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing